Indian pharma has little reason to fear Trump

US tariff threats on Indian generic drugs face significant obstacles. These duties could increase American healthcare costs and potentially cause shortages. Indian firms operate on low margins, making tariff absorption difficult. Recent US manufacturing experiences offer little incentive for relocation. Targeted incentives offer a more direct approach to supply chain resilience.